Upload
nguyendiep
View
216
Download
2
Embed Size (px)
Citation preview
Chemistry & Biology, Volume 22
Supplemental Information
Probes to Monitor Activity of the Paracaspase MALT1
Janna Hachmann, Laura E. Edgington-Mitchell, Marcin Poreba, Laura E. Sanman, Marcin Drag, Matthew Bogyo, and Guy S. Salvesen
Supplemental Information
Supplemental Figures
Figure S1 (related to Figure 1)
LCMS of biotin-LVSR-AOMK
TIC of +Q1: from Sample 54 (biotin-LVSR-AOMK pure) of 1208_Laura.wiff (Turbo Spray) Max. 6.2e8 cps.
1 2 3 4 5 6 7 8 9 10 11 12
Time, min
0.0
1.0e8
2.0e8
3.0e8
4.0e8
5.0e8
6.0e8
Inte
nsity, cps
5.35
12.55
2.45
Channel 1 from Sample 54 (biotin-LVSR-AOMK pure) of 1208_Laura.wiff Max. 0.9 %.
0 1 2 3 4 5 6 7 8 9 10 11 12
Time, min
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
Inte
nsity, %
+Q1: 5.259 to 5.359 min from Sample 54 (biotin-LVSR-AOMK pure) of 1208_Laura.wiff (Turbo Spray) Max. 4.3e6 cps.
100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800
m/z, amu
5.0e5
1.0e6
1.5e6
2.0e6
2.5e6
3.0e6
3.5e6
4.0e6
4.3e6
Inte
nsity, cps
846.4
714.4423.4
133.1
507.4
408.2
312.1
100.9 1692.5864.8439.31270.0295.5 488.8 696.6620.5 1292.7 1441.7930.8719.6 1533.51073.3 1169.5
Acq. File: 1208_Laura.wiff Sample Name: biotin-LVSR-AOMK pure
Sample Number: N/A
Figure S2 (related to Figure 1)
LCMS of Cy5-LVSR-AOMK
TIC of +Q1: from Sample 50 (Cy5 LVSR AOMK final) of 1208_Laura.wiff (Turbo Spray) Max. 2.3e8 cps.
1 2 3 4 5 6 7 8 9 10 11 12
Time, min
0.0
5.0e7
1.0e8
1.5e8
2.0e8
2.3e8
Inte
nsity, cps
5.81
12.53
9.516.36
9.071.11 2.711.706.992.95 4.66 8.685.48 11.637.16
Channel 1 from Sample 50 (Cy5 LVSR AOMK final) of 1208_Laura.wiff Max. 4.6 %.
0 1 2 3 4 5 6 7 8 9 10 11 12
Time, min
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
Inte
nsity, %
5.78
+Q1: 5.659 to 5.860 min from Sample 50 (Cy5 LVSR AOMK final) of 1208_Laura.wiff (Turbo Spray) Max. 2.3e6 cps.
100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800
m/z, amu
2.0e5
4.0e5
6.0e5
8.0e5
1.0e6
1.2e6
1.4e6
1.6e6
1.8e6
2.0e6
2.2e6
Inte
nsity, cps
630.0
1259.2
640.8 1679.1124.3 1574.5839.81126.6
1270.4149.3 371.1 433.1 614.4279.2 1287.0 1519.3686.5 958.6 983.5 1712.0
Acq. File: 1208_Laura.wiff Sample Name: Cy5 LVSR AOMK final
Sample Number: N/A
Figure S3 (related to Figure 2)
The 60 kDa species contains mostly the C-terminal fragment of MALT1 including the caspase-like domain and the Ig3 domain. After mass spectrometry analysis, the frequency with which the different peptides were detected was determined and the amino acids covered by these peptides were calculated. The frequency with which each amino acid was observed in the different peptides was graphed versus the position in full-length MALT1 to determine which part of the protein made up the 60 kDa species. For example, amino acid 41 was discovered in 2 different peptides (encompassing either amino acids 40-52 or 41-52) with a total occurrence of 16. The frequency for this amino acid was thus graphed as 16. DD, death domain; Ig, immunoglobulin-like domain.
0 10 20 30 40 50 60 70 80
Ig1 Ig2DD caspase-like Ig31 824
Freq
uenc
y of
am
ino
acid
det
ectio
n
Figure S4 (related to Figure 3)
MALT1 gets cleaved upon overexpression. MALT1-WT or C464A containing an N- or C-terminal Flag-tag, respectively, were overexpressed in the presence or absence of Bcl10 in HEK-293A cells. Cell lysis was followed by SDS-PAGE and Western blot analysis with the indicated antibodies. Note that when Bcl10 is expressed in combination with MALT1-WT (lanes 1 and 2) a smaller Bcl10 cleavage product below the main species is visible. The size difference between overexpressed (lanes 1-4) and endogenous (lanes 5-8) Bcl10 is explained by the Flag-tag on the Bcl10 construct.
_-MALT1
_-Bcl10
_-`-tubulin
–– + Flag-MALT1-C464A
MALT1-C464A-FlagBcl10
++
–+ +
–
+–
–
kDa
97 -
31 -
97 -
_-Flag
–+ – Flag-MALT1-WT
MALT1-WT-Flag–+–
––
116 -
116 -
–– +
+–
–– –
–
––
––+ –
–+–
––
Supplemental Experimental Procedures
Synthesis of Cy5-LVSR-AOMK and biotin-LVSR-AOMK
All reagents were purchased from commercial suppliers and used without further
purification. All solvents were HPLC grade. Reactions were analyzed by LC-MS using an
API 150EX single-quadropole mass spectrometer (Applied Biosystems). Reverse HPLC
was conducted with an AKTA explorer 100 (Amersham Pharmacia Biotech) using a C18
column.
The method for the synthesis of Cy5-LVSR-AOMK and biotin-LVSR-AOMK was adapted
from a previously described literature procedure (Edgington et al., 2012; Edgington et
al., 2013). Boc-Leu-Val-Ser(OtBu)-Arg(Pbf)-OH was prepared using standard solid
phase peptide synthesis on 2-chlorotrityl resin. This acid was converted to a
chloromethyl ketone (CMK) using the previously described method.
Isobutylchloroformate (25 µL, 0.19 mmol, 1.1 equiv.) was added dropwise to a solution
of Boc-Leu-Val-Ser(OtBu)-Arg(Pbf)-OH (150 mg, 0.17 mmol) and N-methylmorpholine
(23 µL, 0.21 mmol, 1.2 equiv.) in dry THF (1 mL) at -78°C, and the reaction mixture was
stirred for 1 h under argon atmosphere. Diazomethane was prepared from diazald (0.21
g, 0.93 mmol, 5.4 equiv.) and added dropwise to the reaction mixture at 0°C. After 30
min, the reaction was allowed to warm to room temperature, and the reaction mixture
was stirred for 3 h. A 1:1 solution of hydrochloric acid and acetic acid (500 µL) was then
added dropwise while stirring at 0°C. The reaction mixture was diluted with EtOAc, and
the organic phase was washed with water, saturated NaHCO3, and brine. The organic
layer was dried with MgSO4, filtered, and concentrated using a rotary evaporator,
followed by HPLC purification. The resulting CMK was a white powder (10.1 mg, 0.011
mmol, 6.7%). Boc-Leu-Val-Ser(OtBu)-Arg(Pbf)-CMK (10.1 mg, 0.011 mmol) was then
dissolved in 1 mL dry DMF and 2,6-dimethylbenzoic acid (2.5 mg, 0.017 mmol, 1.5
equiv.) was added along with KF (12.7 mg, 0.22 mmol, 20 equiv.). The reaction mixture
was stirred overnight under argon atmosphere at room temperature. The DMF was
removed in vacuo and 25% TFA in DCM was added for 45 min to remove the protecting
groups followed by concentration of the reaction mixture under reduced pressure. The
deprotected intermediate was then purified by HPLC to yield a white powder (2.7 mg,
0.004 mmol, 39%), which was divided into two aliquots. To one aliquot, Cy5-OSu was
coupled by published methods (Edgington et al., 2012; Edgington et al., 2013) followed
by HPLC purification to yield the compound Cy5-LVSR-AOMK (LE40) (1.7 mg, 0.001
mmol, 63%), a blue powder. To the other aliquot, Biotin-OSu was added according to the
same method and purified by HPLC to yield the compound biotin-LVSR-AOMK (LE42) (1
mg, 0.001 mmol, 54%), a white powder.
Mass spectrometry analysis
Mass spectrometry analysis of proteins extracted from SDS-PAGE gels has been
described elsewhere (Sacchetti et al., 2013). The analysis was performed by the
proteomics core facility at Sanford-Burnham Medical Research Institute. Briefly, the
coomassie-stained protein bands were excised from the gel and subjected to in-gel
trypsin digestion using mass spectrometry grade trypsin (Promega). The digested
samples were analyzed by 1D-LC/MS/MS using an LTQ linear ion trap mass
spectrometer (Thermo Scientific). MS/MS spectra were searched against the Human IPI
database using Sorcerer Enterprise with SEQUEST (SageN) software. The minimum
trans-proteomic pipeline (TPP) probability score for proteins to 0.95 was set to assure a
very low error rate (much less than FDR 1%) with reasonably good sensitivity.
Supplemental References
Edgington, L.E., van Raam, B.J., Verdoes, M., Wierschem, C., Salvesen, G.S., and Bogyo, M. (2012). An optimized activity-based probe for the study of caspase-6 activation. Chem Biol 19, 340-352.
Edgington, L.E., Verdoes, M., Ortega, A., Withana, N.P., Lee, J., Syed, S., Bachmann, M.H., Blum, G., and Bogyo, M. (2013). Functional imaging of legumain in cancer using a new quenched activity-based probe. J Am Chem Soc 135, 174-182.
Sacchetti, C., Motamedchaboki, K., Magrini, A., Palmieri, G., Mattei, M., Bernardini, S., Rosato, N., Bottini, N., and Bottini, M. (2013). Surface polyethylene glycol conformation influences the protein corona of polyethylene glycol-modified single-walled carbon nanotubes: potential implications on biological performance. ACS nano 7, 1974-1989.